Lydia Nakiyingi1, Vineshree Mischka Moodley, Yukari C Manabe, Mark P Nicol, Molly Holshouser, Derek T Armstrong, Widaad Zemanay, Welile Sikhondze, Olive Mbabazi, Bareng A S Nonyane, Maunank Shah, Moses L Joloba, David Alland, Jerrold J Ellner, Susan E Dorman. 1. *Department of Medicine, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; †Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa and National Health Laboratory Service, South Africa; ‡Johns Hopkins University School of Medicine, Baltimore, MD; §Department of Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD; ‖Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda; ¶Division of Infectious Diseases, Department of Medicine, New Jersey Medical School, Newark, NJ; and #Department of Medicine, Boston Medical Center, Boston University, Boston, MA.
Abstract
OBJECTIVE: In settings of high HIV prevalence, tuberculosis control and patient management are hindered by lack of accurate, rapid tuberculosis diagnostic tests that can be performed at point-of-care. The Determine TB LAM Ag (TB LAM) test is a lateral flow immunochromatographic test for detection of mycobacterial lipoarabinomannan (LAM) in urine. Our objective was to determine sensitivity and specificity of the TB LAM test for tuberculosis diagnosis. DESIGN: Prospective diagnostic accuracy study. SETTING: Hospital and outpatient settings in Uganda and South Africa. PARTICIPANTS: HIV-infected adults with tuberculosis symptoms and/or signs. METHODS: Participants provided a fresh urine specimen for TB LAM testing, blood for mycobacterial culture, and 2 respiratory specimens for smear microscopy and mycobacterial culture. MAIN OUTCOME MEASURES: For the TB LAM test, sensitivity in participants with culture-positive tuberculosis and specificity in participants without tuberculosis. RESULTS: A total of 1013 participants were enrolled. Among culture-positive tuberculosis patients, the TB LAM test identified 136/367 (37.1%) overall and 116/196 (59.2%) in the group with CD4 ≤100 cells per cubic millimeter. The test was specific in 559/573 (97.6%) patients without tuberculosis. Sensitivity of the urine TB LAM test plus sputum smear microscopy was 197/367 (53.7%) overall and 133/196 (67.9%) among those with CD4 ≤100. CD4 ≤50 [adjusted odds ratio (AOR), 6.2; P < 0.001] or 51-100 (AOR, 7.1; P < 0.001), mycobacteremia (AOR, 6.1; P < 0.01) and hospitalization (AOR, 2.6; P = 0.03) were independently associated with a positive TB LAM test. CONCLUSIONS: In HIV-positive adults with CD4 ≤100, the TB LAM urine test detected over half of culture-positive tuberculosis patients, in <30 minutes and without the need for equipment or reagents.
OBJECTIVE: In settings of high HIV prevalence, tuberculosis control and patient management are hindered by lack of accurate, rapid tuberculosis diagnostic tests that can be performed at point-of-care. The Determine TB LAM Ag (TB LAM) test is a lateral flow immunochromatographic test for detection of mycobacterial lipoarabinomannan (LAM) in urine. Our objective was to determine sensitivity and specificity of the TB LAM test for tuberculosis diagnosis. DESIGN: Prospective diagnostic accuracy study. SETTING: Hospital and outpatient settings in Uganda and South Africa. PARTICIPANTS: HIV-infected adults with tuberculosis symptoms and/or signs. METHODS:Participants provided a fresh urine specimen for TB LAM testing, blood for mycobacterial culture, and 2 respiratory specimens for smear microscopy and mycobacterial culture. MAIN OUTCOME MEASURES: For the TB LAM test, sensitivity in participants with culture-positive tuberculosis and specificity in participants without tuberculosis. RESULTS: A total of 1013 participants were enrolled. Among culture-positive tuberculosispatients, the TB LAM test identified 136/367 (37.1%) overall and 116/196 (59.2%) in the group with CD4 ≤100 cells per cubic millimeter. The test was specific in 559/573 (97.6%) patients without tuberculosis. Sensitivity of the urine TB LAM test plus sputum smear microscopy was 197/367 (53.7%) overall and 133/196 (67.9%) among those with CD4 ≤100. CD4 ≤50 [adjusted odds ratio (AOR), 6.2; P < 0.001] or 51-100 (AOR, 7.1; P < 0.001), mycobacteremia (AOR, 6.1; P < 0.01) and hospitalization (AOR, 2.6; P = 0.03) were independently associated with a positive TB LAM test. CONCLUSIONS: In HIV-positive adults with CD4 ≤100, the TB LAM urine test detected over half of culture-positive tuberculosispatients, in <30 minutes and without the need for equipment or reagents.
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Maunank Shah; Ebrahim Variava; Charles B Holmes; Alison Coppin; Jonathan E Golub; Jeremy McCallum; Michelle Wong; Binu Luke; Desmond J Martin; Richard E Chaisson; Susan E Dorman; Neil A Martinson Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet Journal: Ann Intern Med Date: 2003-01-07 Impact factor: 25.391
Authors: Stephen D Lawn; David J Edwards; Katharina Kranzer; Monica Vogt; Linda-Gail Bekker; Robin Wood Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu Journal: BMC Infect Dis Date: 2014-01-02 Impact factor: 3.090
Authors: Janneke A Cox; Robert L Lukande; Sam Kalungi; Eric Van Marck; Martin Lammens; Koen Van de Vijver; Andrew Kambugu; Ann M Nelson; Robert Colebunders; Yukari C Manabe Journal: J Clin Microbiol Date: 2015-06-10 Impact factor: 5.948
Authors: Yukari C Manabe; William Worodria; Frank van Leth; Harriet Mayanja-Kizza; Afsatou Ndama Traore; Josefo Ferro; Nadine Pakker; Matthias Frank; Martin P Grobusch; Robert Colebunders; Frank Cobelens Journal: Am J Trop Med Hyg Date: 2016-10-17 Impact factor: 2.345
Authors: Christina Yoon; Fred C Semitala; Lucy Asege; Jane Katende; Sandra Mwebe; Alfred O Andama; Elly Atuhumuza; Martha Nakaye; Derek T Armstrong; David W Dowdy; Charles E McCulloch; Moses Kamya; Adithya Cattamanchi Journal: Am J Respir Crit Care Med Date: 2019-03-01 Impact factor: 21.405
Authors: Stephanie Bjerrum; Ian Schiller; Nandini Dendukuri; Mikashmi Kohli; Ruvandhi R Nathavitharana; Alice A Zwerling; Claudia M Denkinger; Karen R Steingart; Maunank Shah Journal: Cochrane Database Syst Rev Date: 2019-10-21
Authors: Paul K Drain; Elena Losina; Sharon M Coleman; Janet Giddy; Douglas Ross; Jeffrey N Katz; Ingrid V Bassett Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731